-
Mashup Score: 102Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer - 3 day(s) ago
British Journal of Cancer – Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Overcoming barriers to single-cell RNA sequencing adoption in low- and middle-income countries - 8 day(s) ago
European Journal of Human Genetics – Overcoming barriers to single-cell RNA sequencing adoption in low- and middle-income countries
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57Increased Biomarker Uptake Needed to Further Realize Potential of Precision Medicine - ILCN.org (ILCN/WCLC) - 11 day(s) ago
Drs. Christian Rolfo and Valeria Denninghoff contend that data show improvements in outcomes from personalized treatment may have stalled and that increased testing for driver genes alterations is needed.
Source: www.ilcn.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2JCO Precision Oncology Conversations: Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment - 30 day(s) ago
author Dr. Christian Rolfo shares insights into his JCO PO article, â.â Host Dr. Rafeh Naqash and Dr. Rolfo discuss how early liquid biopsy in aNSCLC in parallel with path dx is associated with shorter time to treatment. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to , where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I’m your host, Dr. Rafeh Naqash, Social Media Editor for and Assistant Professor at the Stephenson Cancer Center, University of Oklahoma.  Today we are thrilled to be joined by Dr. Christian Rolfo, Associate Director of Clinical Research at the Center of Thoracic Oncology at the Tisch Cancer Institute at Mount Sinai Health System. He is also the lead author of the JCO Precision Oncology article entitled “.” Our guest’s disclosures will be linked in the transcript. Christian, it’s great to have you here. Welcome to our podcast and we are excited to learn about some of the interesting results from you
Source: sites.libsyn.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation - 1 month(s) ago
AbstractPurpose:. Liquid biopsy (LBx) for tumor profiling is increasingly used, but concerns remain regarding negative results. A lack of results may truly reflect tumor genomics, or it may be a false negative that would be clarified by tissue testing. A method of distinguishing between these scenarios could help clarify when follow-on tissue testing is valuable.Experimental Design:. Here we evaluate circulating tumor DNA (ctDNA) tumor fraction (TF), a quantification of ctDNA in LBx samples, for utility in identifying true negative results. We assessed concordance between LBx and tissue-based results, stratified by ctDNA TF, in a real-world genomic dataset of paired samples across multiple disease types. We also evaluated the frequency of tissue results identifying driver alterations in patients with lung cancer after negative LBx in a real-world clinicogenomic database.Results:. The positive percent agreement and negative predictive value between liquid and tissue samples for driver a
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation - 1 month(s) ago
AbstractPurpose:. Liquid biopsy (LBx) for tumor profiling is increasingly used, but concerns remain regarding negative results. A lack of results may truly reflect tumor genomics, or it may be a false negative that would be clarified by tissue testing. A method of distinguishing between these scenarios could help clarify when follow-on tissue testing is valuable.Experimental Design:. Here we evaluate circulating tumor DNA (ctDNA) tumor fraction (TF), a quantification of ctDNA in LBx samples, for utility in identifying true negative results. We assessed concordance between LBx and tissue-based results, stratified by ctDNA TF, in a real-world genomic dataset of paired samples across multiple disease types. We also evaluated the frequency of tissue results identifying driver alterations in patients with lung cancer after negative LBx in a real-world clinicogenomic database.Results:. The positive percent agreement and negative predictive value between liquid and tissue samples for driver a
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 49May ctDNA tumour fraction help interpret negative results? - 1 month(s) ago
A methodology shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue test
Source: dailyreporter.esmo.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 44Moving Forward Liquid Biopsy in Early Liver Cancer Detection - 1 month(s) ago
Summary:. Early cancer detection is an attractive and promising application for liquid biopsy that might revolutionize cancer screenings. In this issue of Cancer Discovery, Foda and colleagues expand the potential utility of a machine learning fragmentome-based model, called DELFI, for detecting liver cancer in high-risk patients.See related article by Foda et al., p. 616 (5).
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42Moving Forward Liquid Biopsy in Early Liver Cancer Detection - 1 month(s) ago
Summary:. Early cancer detection is an attractive and promising application for liquid biopsy that might revolutionize cancer screenings. In this issue of Cancer Discovery, Foda and colleagues expand the potential utility of a machine learning fragmentome-based model, called DELFI, for detecting liver cancer in high-risk patients.See related article by Foda et al., p. 616 (5).
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 51
Since 2012 when immune checkpoint inhibitors reported the first signals of activity in advanced nonâsmall cell lung cancer (NSCLC),1,2 immunotherapy has progressively revolutionized the therapeutic landscape of this disease moving from pretreated metastatic disease to earlier stages, including the…
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
đŁ Our paper âRecommendations for reporting tissue & circulating tumour (ct)DNA NGS results in NSCLCâ is online @BrJCancer @Nature @UmbertoMalapel1 @Alfdoc2 @olakhorshid @hausruck1 Natasha Leighl, Nir Peled, Egbert Smit, & a great team @isliquidbiopsy https://t.co/LSiLZxhNAG